Financials
Financial year 2026
Invigo Therapeutics from Mechelen, company number BE0789481317, closed financial year 2026 with a result of € 9,011 after tax. For that financial year Invigo Therapeutics recorded a gross margin of € 9,667 and equity of € 2,055. Compared with financial year 2025, the result moved from € -16,600 to € 9,011. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 28, 2026.
€ 2,055
▲ € 9,011 vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 9,011
▲ still € 16,600 loss in 2025
Profit after tax over the fiscal year.
€ 2,053
▲ 117% vs 2025
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2026. Retained profit grew to € -7,945.
Debts at end 2026
None
No bank loans on the last day of the fiscal year.
| 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|
| Gross margin | € 300 | € -7,311 | € 9,667 | ▲ € 16,978 |
| Profit after taxes | € -356 | € -16,600 | € 9,011 | ▲ € 25,611 |
| Equity | € 9,644 | € -6,956 | € 2,055 | ▲ € 9,011 |
| Total debts | € 9,215 | € 7,904 | € 0 | ▼ 100% |
| Cash | € 9,788 | € 946 | € 2,053 | ▲ 117% |
| Retained profit | € -356 | € -16,956 | € -7,945 | ▲ € 9,011 |
| Balance sheet total | € 18,858 | € 948 | € 2,055 | ▲ 117% |
Key figures of Invigo Therapeutics, fiscal years 2024 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to Invigo Therapeutics?
What happened at Invigo Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: profit of € 9,011. Source: NBB ↗
- New establishment in Mechelen. KBO
- Start of the company according to the CBE. KBO
In short
From € 356 loss in 2024 to € 9,011 profit in 2026.
Best year ever: 2026, with € 9,011 profit.
Management
Behind Invigo Therapeutics is LIFE of SCI BV. LIFE of SCI BV is also behind Temmune Therapeutics.
Directors
According to the 2026 annual accounts
Establishments
Establishment units
Physical locations of this company
Nonnenstraat 23
2800 Mechelen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0789.481.317
- VAT number
- BE 0789.481.317
- Registered office
- Nonnenstraat 23, 2800 Mechelen
- Names & denominations
- Invigo Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 8 August 2022
- Peppol
- Active · Active since 12 Dec 2025
- Activities · NACE
Vervaardiging van overige farmaceutische producten
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Vervaardiging van geneesmiddelen
Overige gespecialiseerde wetenschappelijke en technische activiteiten